Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: A review

Brain Research Bulletin

Volumn 81, Issue 2-3, 2010, Pages 236-247

  McLaughlin, Patricia J ^a   Sassani, Joseph W ^a   Klocek, Matthew S ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cornea; Diabetes; Naltrexone; Opioids; Wound healing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ENDORPHIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INSULIN; MESSENGER RNA; METENKEPHALIN; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALCOHOLISM; CELL DIVISION; CELL PROLIFERATION; CELL RENEWAL; CORNEA EPITHELIUM; CORNEA INJURY; DIABETES CONTROL; DIABETIC KERATOPATHY; DNA SYNTHESIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENZYME REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KERATOPATHY; MORNING DOSAGE; NON INVASIVE MEASUREMENT; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REVIEW; WOUND HEALING;

ANALGESICS, OPIOID; ANIMALS; CORNEAL DISEASES; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; EPITHELIUM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; WOUND HEALING;

EID: 73149105301     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.08.008     Document Type: Review

References (137)

1. Akimoto Y., Kawakami H., Yamamoto K., Munetomo E., Hida T., and Hirano H. Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3802-3809
2. Alexander C.M., Howell E.W., Bissell M.J., and Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. 135 (1996) 1669-1677
3. Aschner P. Current concepts of diabetes mellitus. Int. Ophthalmol. Clin. 38 (1998) 1-10
4. Azar D.T., Spurr-Michaud S.J., Tisdale A.S., and Gipson I.K. Decreased penetration of anchoring fibrils into the diabetic stroma. A morphometric analysis. Arch. Ophthalmol. 107 (1989) 1520-1523
5. Berman Y., Devi L., and Carr K.D. Effects of streptozotocin-induced diabetes on prodynorphin-derived peptides in rat brain regions. Brain Res. 685 (1995) 129-134
6. Berman Y., Devi L., Spangler R., Kreek M.J., and Carr K.D. Chronic food restriction and streptozotocin-induced diabetes differentially alter prodynorphin mRNA levels in rat brain regions. Mol. Brain Res. 46 (1997) 25-30
7. Brecha N., Karten H.J., and Laverack C. Enkephalin-containing amacrine cells in the avian retina: immunohistochemical localization. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 3010-3014
8. Brightbill F.S., Myers F.L., and Bresnick G.H. Postvitrectomy keratopathy. Am. J. Ophthalmol. 85 (1978) 651-655
9. Bruni J.F., Watkins W.B., and Yen S.S.C. β-endorphin in the human pancreas. J. Clin. Endocrinol. Metab. 49 (1979) 649-651
10. Chase H.P., Jackson W.E., Hoops S.L., Cockerham R.S., Archer P.G., and O'Brien D. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261 (1989) 1155-1160
11. Cheng F., McLaughlin P.J., Banks W.A., and Zagon I.S. Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. Am. J. Physiol. Integr. Comp. Physiol 297 (2009) R844-R852
12. Cheng F., McLaughlin P.J., Verderame M.F., and Zagon I.S. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol. Cancer 7 (2008) 5-17
13. Cheng F., McLaughlin P.J., Verderame M.F., and Zagon I.S. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol. Biol. Cell 20 (2009) 319-327
14. Cheng F., Zagon I.S., Verderame M.F., and McLaughlin P.J. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res. 67 (2007) 10511-10518
15. Cheung C.Y., and Tang F. The effect of streptozotocin-diabetes on β-endorphin level and proopiomelanocortin gene expression in the rat pituitary. Neurosci. Lett. 261 (1999) 118-120
16. Chikama T., Wakuta M., Liu Y., and Nishida T. Deviated mechanism of wound healing in diabetic corneas. Cornea 26 Suppl. 1 (2007) S75-S81
17. Chou L., Cohen E.J., Laibson P.R., and Rapuano C.J. Factors associated with epithelial defects after penetrating keratoplasty. Ophthalmic Surg. 25 (1994) 700-703
18. Chung J., Tolentino F.I., Cajita V.N., Acosta J., and Refojo M.F. Reevaluation of corneal complications after closed vitrectomy. Arch. Ophthalmol. 106 (1988) 916-919
19. Cisarik-Fredenburg P. Discoveries in research on diabetic keratopathy. Optometry 72 (2001) 691-704
20. Clark C.M., and Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N. Engl. J. Med. 332 (1995) 1210-1217
21. Courteix C., Bourget P., Caussade F., Bardi M., Coudore F., Fialip J., and Eschalier A. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?. J. Pharmacol. Exp. Ther. 285 (1998) 63-70
22. Daniels J.T., Geerling G., Alexander R.A., Murphy G., Khaw P.T., and Saarialho-Kere U. Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp. Eye Res. (2003) 653-664
23. Datiles M.B., Kador P.F., Fukui H.N., Hu T.-S., and Kinoshita J.H. Corneal re-epithelialization in galactosemic rats. Invest. Ophthalmol. Vis. Sci. 24 (1983) 563-569
24. Diabetes Control, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
25. El-Salhy M., and Spangeus A. Neuropeptide contents in the duodenum of non-obese diabetic mice. Acta Diab. 35 (1998) 9-12
26. Engerman R.L., Bloodworth J.M., and Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26 (1977) 760-769
27. Engerman R.L., and Kern T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36 (1987) 808-812
28. Expert Committee on the Diagnosis, Classification of Diabetes Mellitus. The report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
29. Fallucca F., Tonnarini G., Di Biase N., D'Alessandro M., and Negri M. Plasma met-enkephalin levels in diabetic patients: influence of autonomic neuropathy. Metabolism 45 (1996) 1065-1068
30. Feman S.S. Diabetes and the eye. In: Tasman W., and Jaeger E.A. (Eds). Duane's Clinical Ophthalmology vol. 5 (2000), Lippincott, Williams & Wilkins, Baltimore 1-10
31. Feurle G.E., Helmstaedter V., and Weber U. Met- and leu-enkephalin immuno- and bioreactivity in human stomach and pancreas. Life Sci. 31 (1982) 2961-2969
32. Foulks G.N., Thoft R.A., Perry H.D., and Tolentino F.I. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch. Ophthalmol. 97 (1979) 1076-1078
33. Friend J., Ishii Y., and Thoft R.A. Corneal epithelial changes in diabetic rats. Ophthalmic Res. 14 (1982) 269-278
34. Friend J., and Thoft R.A. The diabetic cornea. Int. Ophthalmol. Clin. 24 (1984) 111-123
35. Fujita H., Morita I., Takase H., Ohno-Matsui K., and Mochizuki M. Prolonged exposure to high glucose impaired cellular behavior of normal human corneal epithelial cells. Curr. Eye Res. 27 (2003) 197-203
36. Fukushi S., Merola L.O., Tanaka M., Datiles M., and Kinoshita J.H. Reepthelialization of denuded corneas in diabetic rats. Exp. Eye Res. 31 (1980) 611-621
37. Giancotti F.G. Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr. Opin. Cell Biol. 9 (1997) 691-700
38. Gipson I.K., Grill S.M., Spurr S.J., and Brennan S.J. Hemidesmosome formation in vitro. J. Cell Biol. 97 (1983) 849-857
39. Gipson I.K., Spurr-Mirchaud S.J., and Tisdale A.S. Anchoring fibrils form a complex network in human and rabbit cornea. Invest. Ophthalmol. Vis. Sci. 289 (1987) 212-221
40. Gipson I.K., and Sugrue S.P. Cell biology of the corneal epithelium. In: Albert D.M., and Jakobiec F.A. (Eds). Principles and Practice of Ophthalmology (1994), Basic Sciences Saunders, Philadelphia 3-16
41. Goebbels M., and Spitznas M. Endothelial barrier function after pacoemulsification: a comparison between diabetic and non-diabetic patients. Graefes Arch. Clin. Exp. Ophthalmol. 229 (1991) 254-257
42. Goebbels M., Spitznas M., and Oldendoerp J. Impairment of corneal epithelial barrier function in diabetics. Graefes Arch. Clin. Exp. Ophthalmol. 90 (1980) 463-468
43. Graham C.R., Richard R.D., and Varma S.D. Oxygen consumption by normal and diabetic rat and human corneas. Ophthalmol. Res. 13 (1981) 65-71
44. Greenberg J., Ellyin F., Pullen G., Ehrenpreis S., Singh S.P., and Cheng J. Methionine-enkephalin and β-endorphin levels in brain, pancreas, and adrenals of db/db mice. Endocrinology 116 (1985) 328-331
45. Grover V.S., Sharma A., and Singh M. Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice. Eur. J. Pharmacol. 399 (2000) 161-164
46. Guigliano D., Quatraro A., Consoli G., Ceriello A., Torella R., and D'Onofrio F. Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non insulin-dependent diabetic subjects. Metab. Clin. Exp. 36 (1987) 286-289
47. Hallberg C.K., Trocme S.D., and Ansari N.H. Acceleration of corneal wound healing in diabetic rats by the antioxidant trolox. Res. Commun. Mol. Pathol. Pharmacol. 93 (1996) 3-12
48. Hatchell D.L., Magolan J.J., Besson M.J., Goldman A.I., Pederson H.J., and Schultz K.J. Damage to the epithelial basement membrane in the corneas of diabetic rabbits. Arch. Ophthalmol. 101 (1983) 469-471
49. Herse P.R. A review of manifestations of diabetes mellitus in the anterior eye and cornea. Am. J. Optom. Physiol. Opt. 65 (1988) 224-230
50. Hyndiuk R.A., Kazarian E., Schultz R.O., and Seideman S.A. Neurotrophic corneal ulcers in diabetes mellitus. Arch. Ophthalmol. 95 (1977) 2193-2196
51. Isayama T., McLaughlin P.J., and Zagon I.S. Endogenous opioids regulate cell proliferation in the retina of developing rat. Brain Res. 544 (1991) 79-85
52. Isayama T., and Zagon I.S. Localization of preproenkephalin A mRNA in the neonatal rat retina. Brain Res. Bull. 27 (1991) 805-808
53. Jeng S., Lee J.S., and Huang S.C. Corneal decompensation after argon laser iradectomy-a delayed complication. Ophthalmic Surg. 22 (1991) 565-569
54. Kabosova A., Kramerov A.A., Aoki A.M., Murphy G., Zierske J.D., and Ljubimov A.V. Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp. Eye Res. 77 (2003) 211-217
55. Kaji Y. Prevention of diabetic keratopathy. Br. J. Ophthalmol. 89 (2005) 254-255
56. Kaji Y., Usui T., Oshika T., Matsubara M., Yamashita H., Araie M., Murata T., Ishibashi T., Nagai R., Horiuchi S., and Amano S. Advanced glycation end products in diabetic cornea. Invest. Ophthamol. Vis. Sci. 41 (2000) 362-368
57. Kamei J., Kawashima N., and Kasuya Y. Paradoxical analgesia produced by naloxone in diabetic mice is attributable to supersensitivity of δ-opioid receptors. Brain Res. 592 (1992) 101-105
58. Kaufman H.E., Barron B.A., McDonald M.B., and Waltman S.T. The Cornea (1988), Livingstone, New York
59. Kim E.M., Grace M.K., Welch C.C., Billington C.J., and Levine A.S. STZ-induced diabetes decreases and insulin normalizes POMC mRNA in arcuate nucleus and pituitary in rats. Am. J. Physiol. 276 (1999) R1320-R1326
60. Kim H.S., Shang T., Chen Z., Pflugfelder S.C., and Li D.Q. TG-β1 stimulates the production of gelatinase (MMP-9), collagenases (MMP-1, -13) and stromelysins (MMP-3, -10, -11) by human corneal epithelial cells. Exp. Eye Res. 79 (2004) 263-274
61. Klein R., Klein B.E., Moss S.E., Davis M.D., and DeMets D.L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260 (1988) 2864-2871
62. Klocek M.S., Sassani J.W., McLaughlin P.J., and Zagon I.S. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J. Ocular Pharmacol. Ther. 23 (2007) 89-102
63. M.S. Klocek, J.W. Sassani, P.J. McLaughlin, I.S. Zagon, Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type 1 diabetic rats, Exp. Eye Res., in press, Jul 1, Epub ahead of print.
64. Kolta M.G., Pierzchala K., Houdi A.A., and Van Loon G.R. Effect of diabetes on the levels of two forms of met-enkephalin in plasma and peripheral tissues of the rat. Neuropeptides 21 (1992) 55-63
65. Krampert M., Bloch W., Sasaki T., Bugnon P., Rulicke T., Wolf E., Aumailley M., Parks W.C., and Werner S. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol. Biol. Cell 15 (2004) 5242-5254
66. Ljubimov A.V., Alba S.A., Burgeson R.E., Ninomiay Y., Sado Y., Sun T.-T., Nesburn A.B., Kenney M.C., and Maguen E. Extracellular matrix changes in human corneas after radial keratomy. Exp. Eye Res. 67 (1998) 265-272
67. Ljubimov A.V., Burgeson R.E., Butkowski R.J., Couchman J.R., Zardi L., Ninomiya Y., Sado Y., Huang Z.S., Nesburn A.B., and Kenney M.C. Basement membrane abnormalities in human eyes with diabetic retinopathy. J. Histochem. Cytochem. 44 (1996) 1469-1479
68. Ljubimov A.V., Huang Z., Huang G.H., Burgeson R.E., Gullberg D., Miner J.H., Ninomiya Y., Sado Y., and Kenney M.C. Human corneal epithelial basement membrane and integrin alterations in diabetes and diabetic retinopathy. J. Histochem. Cytochem. 46 (1998) 1033-1041
69. Lu W.N., Ebihara N., Miyazaki K., and Murakami A. Reduced expression of laminin-5 in corneal epithelial cells under high glucose condition. Cornea 25 (2006) 61-67
70. Maguen E., Rabinowitz Y.S., Regev L., Saghizadeh M., Sasaki T., and Ljubimov A.V. Alterations of extracellular matrix components and proteinases in human corneal buttons with INTACS for post-laser in situ keratomileusis keratectasia and keratoconus. Cornea 27 (2008) 565-573
71. McDermott A.M., Xiao T.L., Kern T.S., and Murphy C.J. Non-enzymatic glycation in corneas from normal and diabetic donors and its effects on epithelial cell attachment in vitro. Optometry 74 (2003) 443-452
72. McLaughlin P.J., Levin R.J., and Zagon I.S. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int. J. Oncol. 14 (1999) 991-998
73. McLaughlin P.J., and Zagon I.S. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor (OGFr). Int. J. Oncol. 28 (2006) 1577-1583
74. Nakamura M., Sato N., Chikama T., Hasegawa Y., and Nishida T. Fibronectin facilitates corneal epithelial wound healing in diabetic rats. Exp. Eye Res. 64 (1997) 355-359
75. Negri M., Tonnarini G., D'Alessandro M., and Fallucca F. Plasma met-enkephalin in type 1 diabetes. Metabolism 41 (1992) 460-461
76. Niffenegger J.H., Gong D., Cavallerano J., and Aiello L.M. Diabetes mellitus. In: Albert D.M., and Jakobiec F.A. (Eds). Principles and Practice of Ophthalmology vol. 5 (1994), W.B. Saunders Company, Philadelphia 2925-2936
77. Parrish C.M. The cornea in diabetes mellitus. In: Feman S.S. (Ed). Ocular Problems in Diabetes Mellitus (1992), Blackwell Scientific, Boston 179-205
78. Perry H.D., Foulks G.N., Thoft R.A., and Tolentino F.I. Corneal complications after closed vitrectomy through the pars plana. Arch. Ophthalmol. 96 (1978) 1401-1403
79. Pieper G.M., Mizoguchi H., Ohsawa M., Kamei J., Nagase H., and Tseng L.F. Decreased opioid-induced antinociception but unaltered G-protein activation in the genetic-diabetic NOD mouse. Eur. J. Pharmacol. 401 (2000) 375-379
80. Rao G.N., and Siva Reddy Oration P. Diabetic keratopathy. Ind. J. Ophthalmol. 35 (1987) 16-36
81. Rechardt O., Elomaa O., Vaalamo M., Pääkkönen K., Jahkola T., Höök-Nikanne J., Hembry R.M., Häkkinen L., Kere J., and Saarialho-Kere U. Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J. Invest. Dermatol. 115 (2000) 778-787
82. Robertson S.A., and Andrew S.E. Presence of opioid growth factor and its receptor in the normal dog, cat and horse cornea. Vet. Ophthalmol. 6 (2003) 131-134
83. Rogell G.D. Corneal hypesthesia and retinoapthy in diabetes mellitus. Am. Acad. Ophthalmol. 87 (1980) 229-233
84. Rosenburg M.E., Tervo T.M.T., Immonen I.J., Muller L.J., Gronhagen-Riska C., and Vesaluoma J.H. Corneal structure and sensitivity in type 1 diabetes mellitus. Invest. Ophthalmol. 41 (2000) 2915-2921
85. Saghizadeh M., Brown D.J., Castellon R., Chwa M., Huang G.H., Ljubimova J.Y., Rosenberg S., Spirin K.S., Stolitenko R.B., Adachi W., Kinoshita S., Murphy G., Windsor L.J., Kenney M.C., and Ljubimov A.V. Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. Am. J. Pathol. 158 (2001) 723-734
86. Saghizadeh M., Chwa M., Aoki A., Lin B., Pirouzmanesh A., Brown D.J., Ljubimov A.V., and Kenney M.C. Altered expression of growth factors and cytokines in keratoconus, bullous keratopathy and diabetic human corneas. Exp. Eye Res. 73 (2001) 179-189
87. Saghizadeh M., Kramerov A.A., Tajbakhsh J., Aoki A.M., Wang C., Chai N.-N., Ljubimova J.Y., Sasaki T., Sosne G., Carlson M.R.J., Nelson S.F., and Ljubimov A.V. Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest. Ophthamol. Vis. Sci. 46 (2005) 3604-3615
88. Saini J.S., and Khandalavia B. Corneal epithelial fragility in diabetes mellitus. Can. J. Ophthalmol. 30 (1983) 142-146
89. Sanchez-Thorin J.C. The cornea in diabetes mellitus. Int. Ophthalmol. Clin. 38 (1998) 19-36
90. Sassani J.W., Zagon I.S., and McLaughlin P.J. Opioid growth factor modulation of corneal epithelium: uppers and downers. Curr. Eye Res. 26 (2003) 249-262
91. Sato E., Mori F., Igarashi S., Abiko T., Takeda M., Ishiko S., and Yoshida A. Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 24 (2001) 479-482
92. Schultz R.O., Peters M.A., and Sobocinski K. Diabetic keratopathy as a manifestation of peripheral neuropathy. Am. J. Ophthalmol. 96 (1983) 368-371
93. Schultz R.O., Van Horn D.L., Peters M.A., Klewin K.M., and Schutten W.H. Diabetic keratopathy. Trans. Am. Ophthalmol. Soc. 79 (1981) 180-199
94. Schwartz A.L., Martin N.F., and Weber P.A. Corneal decompensation after argon laser iridectomy. Arch. Ophthalmol. 106 (1988/1974) 1572-1574
95. 5]-methionine enkephalin (DAME) in streptozotocin-induced diabetic rats is reversed by insulin replacement. Life Sci. 62 (1998) 2219-2229
96. Slaughter M.M., Mattler J.A., and Gottlieb D.I. Opiate binding sites in the chick, rabbit and goldfish retina. Brain Res. 339 (1985) 39-47
97. Snip R.C., Thoft R.A., and Tolentino F.I. Similar epithelial healing rates of the corneas of diabetic and nondiabetic patients. Am. J. Ophthalmol. 90 (1980) 463-468
98. Stolwijk T.R., Van Best J.A., Boor J.P., Lemkes H.H., and Oosterhuis J.A. Corneal epithelial barrier function after oxybupropane provocation in diabetics. Invest. Ophthalmol. Vis. Sci. 31 (1990) 436-439
99. Suzuki K., Saito J., Yanai R., Yamada N., Chikama T., Seki K., and Nishida T. Cell-matrix and cell-cell interactions during corneal epithelial wound healing. Prog. Ret. Eye Res. 22 (2003) 113-133
100. Tabatabay C.A., Bumbacher M., Baumgartmer B., and Leuenberger P.M. Reduced number of hemidesmosomes in the corneal epithelium of diabetics with proliferative retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 226 (1988) 389-392
101. Takahashi H., Akiba K., Noguchi T., Ohmura T., Takahashi R., Ezure Y., Ohara K., and Zieske J.D. Matrix Metalloproteinase activity is enhanced during corneal wound repair in high glucose condition. Curr. Eye Res. 21 (2000) 608-615
102. Tervo T., Tervo K., and Eranko L. Ocular neuropeptides. Med. Biol. 60 (1982) 53-60
103. Timmers K., Coleman D.L., Voyles N.R., Powell A.M., Rokaeus A., and Recant L. Neuropeptide content in pancreas and pituitary of obese and diabetes mutant mice: strain and sex difference. Metabolism 39 (1990) 378-383
104. Timmers K., Voyles N.R., Zalenski C., Wilkins S., and Recant L. Altered β-endorphin, met- and leu-enkephalins, and enkephalin-containing peptides in pancreas and pituitary of genetically obese diabetic (db/db) mice during development of diabetic syndrome. Diabetes 35 (1986) 1143-1151
105. Vermes I., Steinmetz E., Schoorl J., van der Veen E.A., and Tilders F.J. Increased plasma levels of immunoreactive beta-endorphin and corticotrophin in non-insulin-dependent diabetes. Lancet 2 (1985) 725-726
106. Wakuta M., Morishige N., Chikama T., Seki K., Nagano T., and Nishida T. Delayed wound closure and phenotypic changes in corneal epithelium of the spontaneously diabetic Goto-Kakizaki rat. Invest. Ophthalmol. Vis. Sci. 48 (2007) 590-596
107. Wang P.Y. Control of hyperglycaemia in diabetic rabbits by a combination of implants. J. Biomed. Eng. 13 (1993) 106-112
108. Wanke T., Auinger M., Formanek D., Merkle M., Lahrmann H., Ogris E., Zwich H., and Irsigler K. Defective endogenous opioid response to exercise in type 1 diabetic patients. Metab. Clin. Exp. 45 (1996) 137-142
109. Watanabe H., Katakami C., Miyata S., and Negi A. Corneal disorders in KKAy mouse: a type 2 diabetes model. Jpn. J. Ophthamol. 46 (2002) 130-139
110. Watt C.B., Su Y.Y., and Lam D.M. Opioid pathways in an avian retina. II. Synaptic organization of enkephalin-immunoreactive amacrine cells. J. Neurosci. 5 (1985) 857-865
111. Xu K.-P., Li Y., Ljubimov A.V., and Yu F.-S.X. High glucose suppresses epidermal growth factor receptor/phosphatidylinositol 3-kinase/Akt signaling pathway and attenuates corneal epithelial wound healing. Diabetes 58 (2009) 1077-1085
112. Yue D.K., Hanwell M.A., Satchell P.M., and Turtle J.R. The effect of aldose reductase inhibition in motor nerve conduction velocity in diabetic rats. Diabetes 31 (1982) 789-794
113. Zagon I.S., Isayama T., and McLaughlin P.J. Preproenkephalin mRNA expression in the developing and adult rat brain. Mol. Brain Res. 21 (1984) 85-98
114. Zagon I.S., Jenkins J.B., Lang C.M., Sassani J.W., Wylie J.D., Ruth T.B., Fry J.L., and McLaughlin P.J. Naltrexone, an opioid antagonist, facilitates re-epithelialization of the cornea in diabetic rat. Diabetes 51 (2002) 3055-3062
115. Zagon I.S., Klocek M.S., Sassani J.W., Mauger D.T., and McLaughlin P.J. Corneal safety of topically applied naltrexone. J. Ocular Pharmacol. Ther. 22 (2006) 377-387
116. Zagon I.S., Klocek M.S., Sassani J.W., and McLaughlin P.J. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol. 125 (2007) 1082-1088
117. Zagon I.S., and McLaughlin P.J. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37 (2003) 79-88
118. Zagon I.S., and McLaughlin P.J. Opioids and differentiation in human cancer cells. Neuropeptides 39 (2005) 495-505
119. Zagon I.S., and McLaughlin P.J. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Int. J. Oncol. 29 (2006) 489-494
120. Zagon I.S., Rahn K.A., and McLaughlin P.J. Opioids and migration chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides 41 (2007) 441-452
121. Zagon I.S., Ruth T.B., Leure-duPree A.E., Sassani J.W., and McLaughlin P.J. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res. 967 (2003) 37-47
122. 5]-enkephalin, and the zeta (ζ) opioid receptor in vertebrate cornea. Brain Res. 671 (1995) 105-111
123. Zagon I.S., Sassani J.W., Kane E.R., and McLaughlin P.J. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res. 759 (1997) 92-102
124. Zagon I.S., Sassani J.W., Malefyt K.J., and McLaughlin P.J. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch. Ophthalmol. 124 (2006) 1620-1624
125. Zagon I.S., Sassani J.W., and McLaughlin P.J. Opioid growth factor modulates corneal epithelial growth in tissue culture. Am. J. Physiol. 268 (1995) R942-R950
126. Zagon I.S., Sassani J.W., and McLaughlin P.J. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor. Brain Res. 803 (1998) 61-68
127. Zagon I.S., Sassani J.W., and McLaughlin P.J. Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors. Brain Res. 798 (1998) 254-260
128. Zagon I.S., Sassani J.W., and McLaughlin P.J. Cellular dynamics of corneal wound re-epithelialization in the rat. I. Fate of ocular surface epithelial cells synthesizing DNA prior to wounding. Brain Res. 822 (1999) 149-162
129. Zagon I.S., Sassani J.W., and McLaughlin P.J. Cellular dynamics of corneal wound re-epithelialization in the rat. II. DNA synthesis in the ocular surface epithelium following wounding. Brain Res. 839 (1999) 243-252
130. Zagon I.S., Sassani J.W., and McLaughlin P.J. Reepithelialization of the human cornea is regulated by endogenous opioid. Invest. Ophthalmol. Vis. Sci. 41 (2000) 73-81
131. Zagon I.S., Sassani J.W., and McLaughlin P.J. Insulin treatment ameliorates impaired corneal re-epithelialization in diabetic rats. Diabetes 55 (2006) 1141-1147
132. Zagon I.S., Sassani J.W., and McLaughlin P.J. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea 25 (2006) 821-829
133. Zagon I.S., Sassani J.W., Myers R.L., and McLaughlin P.J. Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium. Brain Res. Bull. 72 (2007) 18-24
134. Zagon I.S., Sassani J.W., Ruth T.B., and McLaughlin P.J. Cellular dynamics of corneal wound re-epithelialization in the rat. III. Mitotic activity. Brain Res. 882 (2000) 169-179
135. Zagon I.S., Sassani J.W., Verderame M.F., and McLaughlin P.J. Particle-mediated gene transfer of OGFr cDNA regulates cell proliferation of the corneal epithelium. Cornea 24 (2005) 614-619
136. 5]-enkephalin, in ocular surface epithelium. Brain Res. 792 (1998) 72-78
137. Zagon I.S., Verderame M.F., and McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 38 (2002) 351-376